hrp0092p2-32 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Pediatric Patients with Heterozygous ALPL Mutation show a Broad Clinical Phenotype

Melanie Brichta Corinna , Wurm Michael , Krebs Andreas , Lausch Ekkehart , Van der Werf-Grohmann Natascha , Schwab Karl Otfried

Introduction: Hypophosphatasia (HPP) is a congenital disorder of the bone and mineral metabolism. It is based on mutations in the ALPL gene, which codes for tissue-unspecific alkaline phosphatase (TNSAP). Methods:The casuistic of 3 children with heterozygous ALPL mutation are presented. The patients were identified by laboratory data screening for reduced AP activity at the Children's Hospital of the University Hospital Freiburg....

hrp0089rfc5.6 | Thyroid | ESPE2018

DUOX2 Deficiency in Quebec: From Life-Threatening Compressive Goiter in Infancy to Lifelong Euthyroidism

Dufort Gabrielle , Larrivee-Vanier Stephanie , Eugene Dardye , De Deken Xavier , Heinimann Karl , Szinnai Gabor , Van Vliet Guy , Deladoey Johnny

Background: Congenital hypothyroidism (CH) caused by DUOX2 deficiency has a wide range of clinical presentations and phenotype-genotype correlations are not always straightforward.Objective: To describe four children from Quebec with biallelic DUOX2 variants and widely variable phenotypes.Design/Methods: Case series of four children seen for evaluation of thyroid function at the endocrinology service of two university hospitals in ...

hrp0086rfc1.5 | Adrenals | ESPE2016

A Novel Animal Model to Study 21-Hydroxylase Deficiency in vivo

Zaucker Andreas , Griffin Aliesha , Storbeck Karl-Heinz , Guran Tulay , Thakur Nazia , Weger Meltem , Taylor Angela , Mueller Ferenc , Krone Nils

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is caused by mutations in the CYP21A2 gene. Steroid 21-hydroxylase deficiency results in impaired synthesis of mineralcorticoids and glucocorticoids (GC), plus androgen excess. Hormonal imbalances in 21OHD are postulated to result in systemic transcriptomic and metabolomic alterations. Such perturbations are likely to be underlying co-morbidities, which are increasingly observed in individua...

hrp0086p1-p551 | Perinatal Endocrinology P1 | ESPE2016

Enhanced Mitochondrial Densities Associate with the Pathobiology of β-Cells in Congenital Hyperinsulinism in Infancy

Han Bing , Salomon-Estebanez Maria , Padidela Raja , Skae Mars , Kadler Karl , Cosgrove Karen , Banerjee Indi , Dunne Mark

Background: Congenital hyperinsulinism in infancy (CHI) is associated with inappropriate insulin release from β-cells. This is causally linked to defects in the ion channel genes ABCC8 and KCNJ11 regulating insulin, but little is known about the metabolic support for sustained insulin exocytosis.Objective and hypotheses: We hypothesised that inappropriate insulin release in CHI would require sustained ATP generation by enhanced mit...

hrp0084p3-1090 | Perinatal | ESPE2015

Crystal Formation in the Meibomian Glands as Diagnostic Proof of Pseudohypoaldosteronism Type I

van der Werf-Grohmann Natascha , Lausch Ekkehart , Wurm Michael , Kannan Cecil , Fuchs Hans , Spiekerkotter Ute , Schwab Karl Otfried

Background: Pseudohypoaldosteronism type I (PHA1) is a rare disease of mineralocorticoid resistance (MR). Neonatal manifestation leads to life-threatening dehydration due to massive salt-loss, acidosis and frequently, failure to thrive. Two clinically and genetically distinct forms exist, namely systemic and renal PHA1 caused by mutations in the subunit genes (SCNN1A, SCNN1B, SCNN1G) of the epithelial sodium channel (ENaC) and mineralocorticoid recep...

hrp0092fc7.6 | Diabetes and Insulin Session 2 | ESPE2019

2017 American Academy of Pediatrics Clinical Practice Guideline: Impact on Prevalence of Arterial Hypertension in Children and Adolescents with Type 1 Diabetes mellitus

Dost Axel , Bechtold Susanne , Fink Katharina , Bonfig Walter , Wiemann Dagobert , Kapellen Thomas Michael , Witsch Michael , Schwab Karl Otfried , Holl Reinhard Walter

Background: In 2017 the American Academy of Pediatrics has introduced a new guideline (AAP 2017) to diagnose arterial hypertension in children, as the blood pressure thresholds for adults had been lowered before. There is a controversy about these new reference levels as other societies have not followed these recommendations. We studied the impact of the new AAP 2017 guideline on prevalence of arterial hypertension (HTN) in children with Type 1 diabetes melli...

hrp0089rfc13.6 | Pituitary, Neuroendocrinology and Puberty 2 | ESPE2018

Close Correlation between Salivary and Blood Steroids in Normal Boys: Salivary Testosterone Best Characterizes Male Puberty

Schwab Karl Otfried , Dickhuth Karoline , Mumm Rebekka , Stier Bernhard , Doerfer Juergen , Grueninger Dirk , Brichta Corinna Melanie , van der Werf-Grohmann Natascha , Wurm Michael , Krebs Andreas

Aims: The golden standard to characterize pubertal maturation is the analysis of steroid hormones in the blood. The aim of the investigation was to assess whether the analysis of salivary steroids is similarly able to characterize male pubertal development.Methods: The investigation included 165 normal boys (mean age 12.7±2.8 years, mean body mass index 19.6±4.2 kg/m2). Pubic hair stages were stratified by Tanner and testicular volum...

hrp0089p2-p002 | Adrenals and HPA Axis P2 | ESPE2018

GnRH-analogue Treatment in Children with Congenital Adrenal Hyperplasia (CAH): Data from a Multicenter CAH Registry

Schreiner Felix , Rohayem Julia , Fricke-Otto Susanne , Golembowski Sven , Jorch Norbert , Schwab Karl Otfried , Warncke Katharina , Zanier Ulrike , on behalf of the German CAH Registry (DGKED-QS)

Background: Final height in patients with congenital adrenal hyperplasia (CAH) is generally assumed to be lower than the population norm. Besides CAH subtype and age at diagnosis, timing of pubertal development is considered to have a significant impact on final height. In most CAH patients, puberty starts within normal ranges, although at a somewhat earlier mean age compared to reference populations. CAH-complicating gonadotropin-dependent precocious puberty has been reported...

hrp0082fc2.5 | Bone & Mineral | ESPE2014

Pharmacokinetics and Pharmacodynamics of a Human Monoclonal Anti-Fibroblast Growth Factor 23 Antibody (KRN23) Following 4 Month Intra-Dose Escalation in Adults with X-Linked Hypophosphatemia

Zhang Xiaoping , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Ito Takahiro , Vergeire Maria , Humphrey Jeffrey , Glorieux Francis , Portale Anthony , Insogna Karl , Peacock Munro , Carpenter Thomas

Background: In X-linked hypophosphatemia (XLH), abnormally elevated serum fibroblast growth factor 23 (FGF23) results in low renal maximum threshold for phosphate reabsorption (TmP/GFR), low serum phosphorus (Pi), inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)2D) and development of rachitic deformities.Methods: Up to four s.c. KRN23 doses were given every 28 days to 28 adults with XLH according to a dose-escalation algorithm (0.05&#1...

hrp0082fc2.6 | Bone & Mineral | ESPE2014

Efficacy and Safety Following 4 Monthly s.c. Doses of a Human Anti-Fibroblast Growth Factor 23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia

Peacock Munro , Imel Erik , Zhang Xiaoping , Ruppe Mary , Weber Thomas , Klausner Mark , Ito Takahiro , Vergeire Maria , Humphrey Jeffrey , Glorieux Francis , Portale Anthony , Insogna Karl , Carpenter Thomas

Background: In X-linked Hypophosphatemia (XLH), abnormally elevated serum Fibroblast Growth Factor 23 (FGF23) results in low renal maximum threshold for phosphate reabsorption (TmP/GFR), low serum phosphorus (Pi), inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)2D) and development of rachitic deformities.Methods: Up to four SC KRN23 doses were given every 28 days to 28 adults with XLH (26 completed) according to a dose-escalation algorithm (0.05&...